| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
aTyr Pharma (NASDAQ:LIFE) reported its Q4 earnings results on Thursday, March 14, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
aTyr Pharma missed estimated earnings by -4.0%, reporting an EPS of $-0.25 versus an estimate of $-0.24.
Revenue was down $10.39 million from the same period last year.
Last quarter the company beat on EPS by $0.03 which was followed by a 3.0% drop in the share price the next day.
Here's a look at aTyr Pharma's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.23 | -0.28 | -0.40 | -0.48 |
| EPS Actual | -0.20 | -0.22 | -0.29 | -0.26 |
| Revenue Estimate | 1.50M | 520K | 300K | 210K |
| Revenue Actual | 353K | 0 | 0 | 10.39M |
To track all earnings releases for aTyr Pharma visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: LIFE
